Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:APLIFNASDAQ:ATNFNASDAQ:MYNZNASDAQ:THAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLIFAppili Therapeutics$0.01-1.9%$0.02$0.01▼$0.03$1.25M-0.5920,560 shs300 shsATNF180 Life Sciences$0.83-4.3%$1.01$0.66▼$17.75$5.04M0.23795,428 shs26,480 shsMYNZMainz Biomed$1.38-1.4%$2.26$0.97▼$22.40$4.75M0.31137,882 shs56,797 shsTHARTharimmune$1.80+2.4%$1.45$0.95▼$6.39$4.80M1.04371,459 shs41,400 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLIFAppili Therapeutics0.00%-2.46%-26.43%-58.30%-65.08%ATNF180 Life Sciences0.00%-3.96%-18.63%-19.02%-49.70%MYNZMainz Biomed0.00%-3.50%-31.51%-57.01%-91.40%THARTharimmune0.00%+34.51%+20.97%+32.54%-48.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLIFAppili TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AATNF180 Life Sciences1.0472 of 5 stars0.05.00.00.02.60.00.6MYNZMainz Biomed3.3269 of 5 stars3.35.00.00.01.60.01.3THARTharimmune3.6343 of 5 stars3.85.00.00.03.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLIFAppili Therapeutics 0.00N/AN/AN/AATNF180 Life Sciences 0.00N/AN/AN/AMYNZMainz Biomed 2.50Moderate Buy$14.00914.49% UpsideTHARTharimmune 3.50Strong Buy$17.00843.13% UpsideCurrent Analyst Ratings BreakdownLatest APLIF, ATNF, MYNZ, and THAR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)6/11/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)5/24/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)5/10/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)4/24/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)4/8/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLIFAppili Therapeutics$70K17.84N/AN/AN/A∞ATNF180 Life SciencesN/AN/AN/AN/A$2.91 per shareN/AMYNZMainz Biomed$890K5.33N/AN/A$2.61 per share0.53THARTharimmuneN/AN/AN/AN/A$0.68 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLIFAppili Therapeutics-$1.89M-$0.02N/A∞N/AN/AN/A-134.60%N/AATNF180 Life Sciences-$6.17MN/A0.00∞N/AN/A-147.32%-76.99%8/11/2025 (Estimated)MYNZMainz Biomed-$21.65M-$65.60N/AN/AN/AN/AN/AN/A7/1/2025 (Estimated)THARTharimmune-$12.20M-$7.88N/A∞N/AN/A-489.33%-264.34%N/ALatest APLIF, ATNF, MYNZ, and THAR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/1/2025N/AMYNZMainz Biomed-$2.80N/AN/AN/AN/AN/A5/15/2025Q1 2025ATNF180 Life SciencesN/A-$0.67N/A-$0.67N/AN/A5/12/2025Q1 2025THARTharimmune-$0.84-$0.99-$0.15-$0.99N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLIFAppili TherapeuticsN/AN/AN/AN/AN/AATNF180 Life SciencesN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/ATHARTharimmuneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLIFAppili TherapeuticsN/A0.140.14ATNF180 Life SciencesN/A1.021.02MYNZMainz Biomed0.141.321.26THARTharimmuneN/A0.670.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLIFAppili TherapeuticsN/AATNF180 Life Sciences4.07%MYNZMainz BiomedN/ATHARTharimmune1.16%Insider OwnershipCompanyInsider OwnershipAPLIFAppili Therapeutics11.84%ATNF180 Life Sciences0.17%MYNZMainz BiomedN/ATHARTharimmune10.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLIFAppili Therapeutics8121.27 million106.91 millionNot OptionableATNF180 Life Sciences76.07 million6.06 millionNo DataMYNZMainz Biomed303.44 millionN/ANot OptionableTHARTharimmune22.66 million2.40 millionNot OptionableAPLIF, ATNF, MYNZ, and THAR HeadlinesRecent News About These CompaniesMonday’s Insider Moves: Top Buys and Sells in US StocksJune 24, 2025 | investing.comTharimmune, Inc. (NASDAQ:THAR) CEO Sireesh Appajosyula Acquires 61,496 SharesJune 24, 2025 | insidertrades.comTharimmune CFO Don Kim ResignsJune 17, 2025 | marketwatch.comTharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of DirectorsJune 17, 2025 | accessnewswire.comATharimmune announces executive changes and new agreementsJune 13, 2025 | investing.comTharimmune advances opioid prophylaxis drug TH104May 7, 2025 | investing.comTharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA FeedbackMay 6, 2025 | accessnewswire.comATharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL ConferencesMay 1, 2025 | accessnewswire.comATharimmune Appoints Clay Kahler and Gary Stetz to its Board of DirectorsApril 30, 2025 | accessnewswire.comATharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA FeedbackApril 28, 2025 | sacbee.comSTharimmune announces board retirements ahead of annual meetingApril 26, 2025 | investing.comTharimmune Inc.: Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of DirectorsApril 15, 2025 | finanznachrichten.deTharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of DirectorsApril 15, 2025 | accessnewswire.comATharimmune reports data on new biparatopic biologicsApril 9, 2025 | bioworld.comBTharimmune announces preclinical data from expanded pipeline with HS1940April 9, 2025 | markets.businessinsider.comTharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) TechnologyApril 7, 2025 | accessnewswire.comATharimmune receives Nasdaq non-compliance noticeApril 6, 2025 | investing.comTharimmune announces FDA feedback on NDA path for TH104April 1, 2025 | markets.businessinsider.comTharimmune announces FDA feedback on TH104 NDA pathApril 1, 2025 | markets.businessinsider.comTharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid ExposureMarch 31, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPLIF, ATNF, MYNZ, and THAR Company DescriptionsAppili Therapeutics OTCMKTS:APLIF$0.01 0.00 (-1.90%) As of 06/27/2025 12:52 PM EasternAppili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.180 Life Sciences NASDAQ:ATNF$0.83 -0.04 (-4.27%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.95 +0.12 (+13.98%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.Mainz Biomed NASDAQ:MYNZ$1.38 -0.02 (-1.43%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.97 -0.41 (-29.86%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.Tharimmune NASDAQ:THAR$1.80 +0.04 (+2.41%) Closing price 06/27/2025 03:51 PM EasternExtended Trading$1.62 -0.19 (-10.40%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
